Key Takeaways
- SOLASTA® Bio now holds 14 granted patents for its peptide-based bioinsecticides, including eight in the U.S. and six in Europe.
- The company reports high efficacy across more than 50 greenhouse and field trials, with results consistently at or above 85% compared to commercial standards.
- New trials in rice, leafy greens, and soft fruit crops demonstrate broad applicability across major geographies.
- No phytotoxicity or negative impact on beneficial insects has been observed in any trials to date.
- SOLASTA® Bio continues U.S. expansion and builds on momentum from its oversubscribed $14 million Series A round in 2024.
SOLASTA® Bio Strengthens IP Portfolio With 14 Granted Patents
SOLASTA® Bio has announced significant progress in expanding its intellectual property portfolio, further securing commercial protection for its next-generation peptide-based bioinsecticides. The company now holds 14 granted patents, including eight in the United States and six in Europe, reinforcing its global IP strategy as it moves toward commercial deployment.
According to SOLASTA® Bio, the expanding patent coverage provides essential validation and commercial security for partners and growers adopting its nature-inspired crop protection technologies.
SOLASTA® Bio Reports Strong Field Trial Performance Across Multiple Crops
Building on more than 50 greenhouse and field trials, SOLASTA® Bio has broadened its trials programme to include rice, leafy greens, and high-value soft fruits. Trials in Thailand targeting plant hoppers in rice crops have delivered promising results, while ongoing trials in the U.S., UK, and Italy continue to demonstrate strong efficacy against Spotted Wing Drosophila in strawberries and other berries.
The company has also expanded trials addressing Lepidoptera and aphids across multiple regions, highlighting the versatility of its peptide-based platform.
Across nearly all trials, SOLASTA® Bio reports efficacy levels at or above 85%, matching or outperforming commercial standards. Importantly, no phytotoxicity has been observed, and trial data show no negative effects on beneficial insects, including pollinators.
SOLASTA® Bio Highlights Global Applicability of Peptide-Based Bioinsecticides
CEO and co-founder Shireen Davies emphasized the significance of the newly granted patents and strong field performance. “These patent grants represent a paradigm shift in crop protection, demonstrating that nature-inspired peptides can be effectively protected for commercial deployment,” she said. “Combined with our expanding field trials programme, these developments position SOLASTA Bio exceptionally well as we advance toward commercialisation.”
Davies noted that trial performance across rice in Asia and soft fruit crops in Europe and the U.S. reflects the global potential of SOLASTA® Bio’s technology platform.
SOLASTA® Bio Advances U.S. Operations and Builds on Series A Momentum
SOLASTA® Bio’s technology is based on insect neuropeptides, which regulate essential physiological functions in target pests such as aphids, whitefly, lepidoptera, and plant hoppers. By disrupting these functions, the company’s bioinsecticides offer targeted control while maintaining safety for the environment and beneficial species like bees.
To support its growing North American activities, the company has recently appointed a new Field Trials Manager in the United States.
These achievements build on SOLASTA® Bio’s momentum following its $14 million Series A funding round in September 2024, backed by Forbion BioEconomy Fund, FMC Ventures, Corteva Catalyst, and other major investors. The company continues to advance toward regulatory readiness and commercial rollout with strong investor support and a growing pipeline of field-proven products.
